Hemophilia A With Inhibitors Clinical Trial
Official title:
A Prospective, Randomized, Cross-over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients With Hemophilia A and Inhibitors
The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00231751 -
The Malmö International Brother Study (MIBS)
|
N/A | |
| Terminated |
NCT02484638 -
Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
|
Phase 2/Phase 3 | |
| Terminated |
NCT00212472 -
International Immune Tolerance Study
|
N/A | |
| Withdrawn |
NCT03002480 -
Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography
|
N/A | |
| Completed |
NCT03093480 -
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
|
Phase 4 | |
| Completed |
NCT02448680 -
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
|
Phase 3 | |
| Active, not recruiting |
NCT01105546 -
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
|
Phase 2 | |
| Completed |
NCT02020369 -
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
|
Phase 3 |